Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020108657 - DRUG CONTAINING LIVER TARGETING SPECIFIC LIGAND AND THYROID HORMONE RECEPTOR AGONIST

Publication Number WO/2020/108657
Publication Date 04.06.2020
International Application No. PCT/CN2019/122318
International Filing Date 02.12.2019
IPC
A61K 47/54 2017.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
54the modifying agent being an organic compound
A61K 47/61 2017.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
56the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
61the organic macromolecular compound being a polysaccharide or a derivative thereof
A61P 1/16 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
16for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
CPC
A61K 47/54
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
54the modifying agent being an organic compound
A61K 47/61
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
56the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
61the organic macromolecular compound being a polysaccharide or a derivative thereof
A61P 1/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
16for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Applicants
  • 厦门甘宝利生物医药有限公司 KYLONOVA (XIAMEN) BIOPHARMA CO., LTD. [CN]/[CN]
Inventors
  • 崔坤元 CUI, Kunyuan
Priority Data
201811452803.530.11.2018CN
Publication Language Chinese (ZH)
Filing Language Chinese (ZH)
Designated States
Title
(EN) DRUG CONTAINING LIVER TARGETING SPECIFIC LIGAND AND THYROID HORMONE RECEPTOR AGONIST
(FR) MÉDICAMENT CONTENANT UN LIGAND SPÉCIFIQUE CIBLANT LE FOIE ET UN AGONISTE DU RÉCEPTEUR DES HORMONES THYROÏDIENNES
(ZH) 含有肝靶向特异性配体和甲状腺素受体激动剂的药物
Abstract
(EN)
Provided is a drug containing a liver targeting specific ligand and a thyroid hormone receptor agonist in its structure, which is a new drug structure formed by linking the liver targeting specific ligand with the thyroid hormone receptor agonist through a branch chain, a linker and a joining chain. Thyroid Hormone Receptors (TRs) are divided into two subtypes, TR-α and TR-β, wherein, TR-β is mainly expressed in liver, and TR-α is mainly expressed in heart, nervous system, etc. In certain embodiments, it is envisaged that the provided drug has the action of liver targeting, can specifically bring the thyroid hormone receptor agonist into liver, without entering heart and other issues, and may thereby avoide side effects caused by the action of the thyroid hormone receptor agonist on other issues, and maintain its therapeutic efficacy in the treatment of lipid metabolism disorders and related complications.
(FR)
L'invention concerne un médicament contenant un ligand spécifique ciblant le foie et un agoniste du récepteur des hormones thyroïdiennes dans sa structure, qui est une nouvelle structure de médicament formée par liaison du ligand spécifique ciblant le foie avec l'agoniste du récepteur des hormones thyroïdiennes par une chaîne ramifiée, un lieur et une chaîne de liaison. Les récepteurs des hormones thyroïdiennes (TR) sont divisés en deux sous-types, TR-α et TR-β, dans lesquels TR-β est principalement exprimé dans le foie et TR-α est principalement exprimé dans le cœur, le système nerveux, etc. Dans certains modes de réalisation, il est envisagé que le médicament fourni a l'action de ciblage du foie, peut spécifiquement amener l'agoniste du récepteur des hormones thyroïdiennes dans le foie, sans entrer dans le cœur ni créer d'autres problèmes, et peut ainsi éviter les effets secondaires provoqués par l'action de l'agoniste du récepteur des hormones thyroïdiennes sur d'autres problèmes, et maintenir son efficacité thérapeutique dans le traitement de troubles du métabolisme lipidique et de complications associées.
(ZH)
提供了结构中含有肝靶向特异性配体和甲状腺素受体激动剂的药物,是通过支链、接头和连接链将肝靶向特异性配体和甲状腺素受体激动剂连接,成为一个新的药物结构。甲状腺激素受体(TRs)分为两个亚型,TR-α和TR-β,其中TR-β主要表达在肝脏,TR-α主要表达在心脏、神经系统等。在某些实施方案中,预期提供的药物具有肝靶向的作用,可以把甲状腺素受体激动剂特异性的带入到肝脏,使其不进入到心脏和其他组织,可以避免甲状腺素受体激动剂对其他组织的作用引发副作用,并保持其治疗脂质代谢紊乱及相关并发症的疗效。
Also published as
Latest bibliographic data on file with the International Bureau